ClinicalTrials.gg
Active, not recruitingNCT06672016Updated Oct 13, 2026

Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential

A Phase 3 interventional study of Transdermal system containing progestin in Female Contraception, sponsored by Mylan Pharmaceuticals Inc. Active, not recruiting at 56 sites in United States. Open to female participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Mylan Pharmaceuticals Inc (part of Viatris Inc.) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,630
Allocation
Not applicable
Ages
16 Years and older
Sex
Female
01

Study summary

The Sponsor is developing a progestin-only contraceptive transdermal system (patch).

The main purpose of this study is to look at how safe the study patch is and how well it works in preventing pregnancy. The study will also look at how well the study patch is tolerated.

The study patch is a transdermal system that contains the active ingredient, progestin.

Read the detailed description

Unintended pregnancy continues to be a significant reproductive health problem worldwide. Although the increase in the availability of longer-acting contraceptive methods has improved the situation, the continuing development of newer safe and effective contraception is crucial for women's health.

The development of a progestin-only contraceptive with more convenient dosing may provide women with additional options. The investigational patch is intended to provide an option for women who may not be able to use estrogen-containing combined hormonal contraceptives

02

Conditions studied

  • Female Contraception

Keywords

  • Female, Contraception, Progestin, Transdermal, Patch
  • Prevent Pregnancy
03

In context

Lead sponsor

Mylan Pharmaceuticals Inc is the lead sponsor of 160 studies on the registry; 1 is open to participants now.

First submitted after Mylan Pharmaceuticals Inc became part of Viatris Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy, post-menarcheal and premenopausal women at risk of pregnancy who are at least 16 years of age.
  2. Desires to avoid pregnancy, is seeking to use hormonal for at least 1 year.
  3. Has negative UPT results at screening and at enrollment visits.
  4. Has normal, regular menstrual cycles that are between 21 and 35 days in duration over the last 6 months.
  5. Engages in regular heterosexual vaginal intercourse (at least once per cycle), with a partner who is not known to be sub fertile or infertile.
  6. Agrees not to use other contraceptives or other methodology to prevent pregnancy during the study.
  7. Able to understand and voluntarily provide written or assent (if the participant is adolescent prior to undergoing any trial related procedure) to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected pregnancy or planning pregnancy during next 12 months.
  2. Participants with known or intolerance to progestins, or any components of the progestin patch.
  3. History or presence of dermal sensitivity to medicated patches or to topical applications including bandages, surgical tape.
  4. Known infertility (current or known history) or history of sterilization in either partner.
  5. Received injectable hormonal therapy within 10 months of study enrollment.
  6. Current use of hormonal contraceptive implants.
  7. Has non-hormonal or hormonal intrauterine device (IUD) in place; or has had a recent IUD removal without one spontaneous menses after removal prior to the date of enrollment.
  8. Recent surgical or medical abortion, miscarriage, ectopic pregnancy, or vaginal or cesarean delivery.
  9. Participants lactating at the time of screening into the study or has occurrence of less than 3 regular menstrual cycles after cessation of lactation.
  10. Anticipates routine use of condoms or any other form of back-up contraception for protection from sexually transmitted infections during the study or for emergency contraception.
  11. Participants having a known to progestin-only contraception.
  12. Known or suspected progestin sensitive malignant or premalignant conditions including but not limited to carcinoma of endometrium, ovary, or fallopian tubes.
  13. Skin abnormality (e.g., tattoo or scar) at all possible application sites.
  14. Long-term treatment with drugs or herbal products that are moderate/strong inducers or inhibitors of .
  15. Has uncontrolled thyroid disorder (thyrotoxicosis or myxedema).
  16. Has diagnosis of hereditary angioedema.
  17. Participants with abnormal significant liver function tests as measured by liver function tests
  18. Has a significantly abnormal cervical cancer screening test.
  19. Participants with chlamydial or gonorrheal infection at screening.
  20. Has unexplained vaginal bleeding within the past 6 months or any abnormal bleeding which is expected to recur during the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,630 participants (estimated)

Study arms

  • Experimental
    This is a single-arm study.

    The study patch is a transdermal system that contains the active ingredient progestin. This study is an open-label, single-arm study. This means that all participants in the study will receive the study patch

    Drug: Transdermal system containing progestin

Interventions

  • DrugTransdermal system containing progestin

    MR-130A-01 transdermal system, patch to be used for female contraception

06

What researchers measure

Primary outcomes

  1. To determine the contraceptive efficacy of progestin only patch when used over 13 cycles

    The primary efficacy endpoint will be pregnancy rate described by Pearl Index (PI). PI is defined as the number of pregnancies per 100 women-years.

    Time frame: 13 cycles [of 4 weeks (28 days)

Secondary outcomes

  1. To determine the efficacy in obese population (Body mass index (BMI) ≥30.0 kg/m2)

    Assessment of PI in obese population (Body mass index (BMI) ≥30.0 kg/m2).

    Time frame: 13 cycles [of 4 weeks (28 days)

  2. To determine the efficacy in non-obese population (Body mass index (BMI) <30.0 kg/m2)

    Assessment of PI in non-obese population (BMI \<30.0 kg/m2).

    Time frame: 13 cycles [of 4 weeks (28 days)

  3. Cycle-wise and cumulative pregnancy rates over 1 year

    Assessment of cycle-wise and cumulative pregnancy rates over 1 year using life table analysis.

    Time frame: 13 cycles [of 4 weeks (28 days)

  4. Method failure PI

    Assessment of method failure PI.

    Time frame: 13 cycles [of 4 weeks (28 days)

  5. Incidence of adverse events and serious adverse events

    Assessment of adverse events and serious adverse events.

    Time frame: 13 cycles [of 4 weeks (28 days)

  6. Incidence of application site reactions

    Assessment of application site reactions.

    Time frame: 13 cycles [of 4 weeks (28 days)

  7. Unscheduled bleeding

    Assessment of number of episode and days of unscheduled bleeding, proportion of participants reporting unscheduled bleeding.

    Time frame: 13 cycles [of 4 weeks (28 days)

  8. Adhesion performance

    Assessment of patch adhesion performance as measured by 'Self-Reported Scoring System of Patch Adhesion Assessment Scale' Scores range from 0 to 4 where score 0 indicates the patch has essentially no lift off the skin and score 4 indicates the patch is detached and is completely off the skin.

    Time frame: 13 cycles [of 4 weeks (28 days)

  9. progestin plasma concentrations

    Evaluation of progestin exposure in the subset of participants. PK samples for evaluation of progestin concentrations will be collected during cycles 2 and 5, for population PK and exposure-response analysis.

    Time frame: 5 cycles [of 4 weeks (28 days)

07

Study locations

56 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for May 2027, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2024
First posted
Nov 4, 2024
StartActual
Jan 13, 2025
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06672016
Responsible party
Sponsor
First posted
Nov 4, 2024
Start date
Jan 13, 2025
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Oct 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion